GlaxoSmithKline plc (GSK)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

GlaxoSmithKline plc (GSK) is up 3.0% since the beginning of the year. At $50 per share, GSK is trading 19.4% below its 52-week high of $62. Investors who bought $1,000 worth of GSK shares 5 years ago would now be looking at an investment worth $1,255.

GlaxoSmithKline plc (GSK) has returned 3.01% so far this year and 27.33% over the past 12 months. Over the last ten years, GSK has returned 3.96% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.

Based on dividend-adjusted daily data since Jul 9, 1986, GSK's average daily return is +0.05%, while the average monthly return is +0.88%. At this rate, an investment would double in approximately 6.6 years.

Historically, 57% of months were positive and 43% were negative. The best month was Jan 1987 with a return of +27.6%, while the worst month was Oct 1987 at -31.6%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 7 months.

On a daily basis, GSK closed higher 49% of trading days. The best single day was Feb 2, 1998 with a return of +16.6%, while the worst single day was Oct 19, 1987 at -22.0%.

GlaxoSmithKline plc has an annualized alpha of 4.61%, beta of 0.69, and R2 of 0.23 versus S&P 500 Index. Calculated based on daily prices since July 10, 1986.

• This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (61.88%) than losses (57.36%) - typical of diversified or defensive assets.
• Beta of 0.69 may look defensive, but with R2 of 0.23 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.23 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

GSK ranks 69 for risk / return — better than 69% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for GlaxoSmithKline plc (GSK) and compare them to S&P 500 Index.

GlaxoSmithKline plc provided a 3.48% dividend yield over the last twelve months, with an annual payout of $1.73 per share. The company has been increasing its dividends for 2 consecutive years.

The table displays the monthly dividend distributions for GlaxoSmithKline plc. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the GlaxoSmithKline plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the GlaxoSmithKline plc was 55.70%, occurring on Aug 13, 1993. Recovery took 769 trading sessions.

The current GlaxoSmithKline plc drawdown is 17.43%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of GlaxoSmithKline plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how GlaxoSmithKline plc is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.